WASHINGTON (dpa-AFX) - Thursday, AbbVie Inc. (ABBV) announced positive
results from the Phase 2 PICCOLO trial, which assessed the investigational
mirvetuximab soravtansine also known as ELAHERE, as a standalone treatment for
heavily treated patients with folate receptor-alpha positive, platinum-sensitive
ovarian cancer or PSOC.

The study successfully achieved its primary endpoint with an objective response
rate of 51.9%. Additionally, the median duration of response, a significant
secondary outcome, was recorded at 8.25 months.

The company stated that Mirvetuximab soravtansine's safety profile aligned with
previous study findings, and no new safety issues were detected.

The company plans to unveil complete data from the PICCOLO study at an upcoming
medical conference.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX